阿比特龙诱发的内分泌病。
Abiraterone-Induced Endocrinopathies.
作者信息
Decamps Scarlett, Lis Rita, Ekanayake Preethika
机构信息
Division of Endocrinology, Diabetes and Metabolism, University of California, San Diego, 9350 Campus Point Drive, La Jolla, CA 92037, USA.
Department of Endocrinology, Diabetes and Metabolism, Veterans' Affairs, 3350 La Jolla Village Drive, San Diego, CA 92161, USA.
出版信息
JCEM Case Rep. 2023 Apr 13;1(2):luad039. doi: 10.1210/jcemcr/luad039. eCollection 2023 Mar.
Abiraterone, a CYP17A1 inhibitor, is used along with prednisone in patients with castration-resistant and castration-sensitive prostate cancer, yielding improved overall and disease-free survival. However, little is documented in the endocrinology literature about the incidences of the endocrine side effects of abiraterone. In this case series, we discuss the diagnosis and management of 3 prostate cancer patients who experienced mineralocorticoid excess and secondary adrenal insufficiency related to abiraterone and prednisone use.
阿比特龙是一种细胞色素P450 17A1（CYP17A1）抑制剂，与泼尼松联合用于去势抵抗性和去势敏感性前列腺癌患者，可改善总生存期和无病生存期。然而，内分泌学文献中关于阿比特龙内分泌副作用发生率的记载很少。在本病例系列中，我们讨论了3例前列腺癌患者的诊断和管理，这些患者出现了与使用阿比特龙和泼尼松相关的盐皮质激素过多和继发性肾上腺功能不全。
Zotero 插件